This article is a correction to:
Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease
Weiwei Lin1,2
Fatemeh Mousavi1
Benjamin C. Blum1,2
Christian F Heckendorf1,2Jarrod Moore1,2Noah Lampl1,2Mark McComb1,2
Sergei Kotelnikov3Wenqing Yin4
Nabil Rabhi2
Matthew D. Layne2
Dima Kozakov3
Vipul C. Chitalia4,5,6
Andrew Emili1,2,7*- 1Center for Network Systems Biology, Boston University, Boston, MA, United States
- 2Department of Biochemistry, Boston University School of Medicine, Boston, MA, United States
- 3Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, United States
- 4Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, United States
- 5Veterans Affairs Boston Healthcare System, Boston, MA, United States
- 6Institute of Medical Engineering and Sciences, Massachusetts Institute of Technology, Cambridge, MA, United States
- 7Department of Biology, Boston University, Boston, MA, United States
A Corrigendum on
Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease
by Lin W, Mousavi F, Blum BC, Heckendorf CF, Moore J, Lampl N, McComb M, Kotelnikov S, Yin W, Rabhi N, Layne MD, Kozakov D, Chitalia VC and Emili A (2023). Front. Pharmacol. 14:1243505. doi: 10.3389/fphar.2023.1243505
In the published article, there was an error in the Funding statement. The current statement is “This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University.”
The correct Funding statement appears below.
“This work was supported by operating funds to AE from the Canadian Institutes of Health Research (FDN-148399) and generous start-up funds from Boston University. This work was also supported by funds to VC from the National Heart Lung and Blood Institute (1R01HL166608).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: metabolomics, proteomics, nLC-MS/MS, ESKD, integrated omics
Citation: Lin W, Mousavi F, Blum BC, Heckendorf CF, Moore J, Lampl N, McComb M, Kotelnikov S, Yin W, Rabhi N, Layne MD, Kozakov D, Chitalia VC and Emili A (2024) Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease. Front. Pharmacol. 15:1376058. doi: 10.3389/fphar.2024.1376058
Received: 24 January 2024; Accepted: 25 January 2024;
Published: 09 February 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Lin, Mousavi, Blum, Heckendorf, Moore, Lampl, McComb, Kotelnikov, Yin, Rabhi, Layne, Kozakov, Chitalia and Emili. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Andrew Emili, YWVtaWxpQGJ1LmVkdQ==